Antisense oligodeoxynucleotides regulating expression of TNF-.alpha.

• US 6,046,319 A
• Filed: 10/22/1998
• Issued: 04/04/2000
• Est. Priority Date: 10/22/1997
• Status: Expired due to Fees

• Current Assignee: University of Manitoba
• Original Assignee: University Technologies International, Inc.
• Inventors: Power, Christopher, Mayne, Michael B.
• Primary Examiner(s): Elliott, George C.
• Assistant Examiner(s): EPPS -SMITH, JANET L
• Application Number:
  US09/176,862
• Time in Patent Office: 530 Days
• Field of Search: 536/23.1, 536/24.3, 536/24.5, 536/24.1, 536/24.31, 536/23.2, 435/91.1, 435/6, 514/44
• US Class Current: 536/24.5
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C12N 15/1136 against growth factors, growth regulators, cytokines, lymphokines or hormones
• CPC Class Codes: C12N 2310/315 Phosphorothioates

Abstract

A synthetic nuclease resistant antisense oligodeoxynucleotide capable of selectively modulating expression of human tumor necrosis factor-alpha by targeting exon sequences flanking donor splice sites, thereby regulating expression of TNF-α in a patient in need of such therapy is provided. In an embodiment either AS-ODN having the sequence set forth in SEQ ID No:4 or SEQ ID No:6 or a combination thereof can be used. The AS-ODN is administered either as the active ingredient in a pharmaceutical composition or by utilizing gene therapy techniques as an expression vector.

Claims

1. A Synthetic nuclease resistant antisense oligodeoxynucleotides having a nucleotide sequence selected from the group consisting of SEQ ID No:

4 and SEQ ID No;

6.

2. The synthetic nuclease resistant antisense oligodeoxynucleotides as set forth in claim 1 having phosphorothioate bonds linking between the four 3'"'"'-terminus nucleotide bases for providing nuclease resistance.